PCSK9 and familial hypercholesterolemia: Further, Rothgangl et al employed LNPs to deliver an ABE and a gRNA targeting Pcsk9, a negative regulator of low-density lipoprotein receptor, to treat familial hypercholesterolemia induced by a gain-of-function mutation of PCSK9.